• Profile
Close

High insulin dosage linked to cancer in Type-1 diabetes patients: JAMA Oncology study

IANS Aug 02, 2022

Higher insulin dose is positively associated with cancer incidence, finds a study.


The study, published in JAMA Oncology, looked at the correlation between daily insulin dose and cancer incidence (the number of new cases) among patients with type 1 diabetes, and also found the association is stronger among those with insulin resistance.

The results showed that traditional metabolic factors such as obesity (represented by body mass index), sugar control (represented by Haemoglobin A1c), and blood pressure control do not associate with cancer incidence in patients with Type-1 diabetes.

"However, cancer incidence was higher for those who took large doses of insulin," said Yuanjie Mao, assistant clinical professor at Ohio University in the US.

Our results implied that clinicians might need to balance the potential cancer risk when treating patients with Type 1 diabetes on a high daily insulin dose or that improving insulin sensitivity may be preferred over simply increasing the insulin dose," he added.

To conduct the study, the team analysed the associations of more than 50 common risk factors such as smoking, alcohol use, exercise, metabolic risk factors, medication use and family history with cancer incidence in 1,303 patients with Type 1 diabetes whose data were collected over 28 years.

The study also found that age and sex are associated with cancer incidence when evaluated separately and that a daily insulin dose posed a higher risk of cancer than age, especially a higher insulin dose.

Specifically, women were found to carry a higher risk than men; however, it was unclear what risk factors may contribute to the higher cancer incidence in Type 1 diabetes.

Although previous studies have concluded that patients with diabetes have a higher risk of cancer in general, this is the first study to explore the associated cancer incidence factors in Type 1 diabetes.

Mao explained:

"Type 1 diabetes accounts for an estimated five to 10 per cent of all diabetes cases, and recent studies in Type 1 diabetes also found a higher incidence of certain cancers such as stomach, liver, pancreas, endometrium and kidney cancers in the population compared with the general population. Whereas, in Type 2 diabetes, the increased risk is attributed to metabolic factors such as obesity, chronic inflammation status, and insulin resistance."

Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay